EUVIMEDEUVIMED entdecken
Multizentrische Studie

“Real-Life” Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study

Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shai Ygna, Mahdi Assaly, Anna Gourevitch, Moshe Gatt, Revital Saban, Pia Raanani, Iuliana Vaxman

Acta Haematologica · 2024

DOI: 10.1159/000542936 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Haematologica, 2024. Verfasst von Gilad Itchaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Meir Medical Center, Kfar-Saba, Israel. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Piperidines, Pyrazoles, Pyrimidines. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Waldenström macroglobulinemia (WM) is a rare indolent lymphoma. Zanubrutinib (ZAN), a second-generation BTK inhibitor, has been approved for the treatment of WM in any line of therapy in 2021. Between November 2020 and January 2022, an expanded access program of ZAN opened in Israel for the treatment of patients with relapsed/refractory (R/R)-WM or those ineligible for chemotherapy or ibrutinib in first line.

Methods

This is a multicenter retrospective study aiming to provide real-world data on ZAN in patients with WM in Israel. Demographic and clinical data were collected and coded from electronic files. Response was evaluated by the investigator’s assessment. As the program closed, patients transitioned to commercial ZAN.

Results

Thirteen patients (12 R/R; 1 treatment-naive) were enrolled across 8 centers in Israel. The median age at ZAN initiation was 71 years (range, 50–85); 6 were males; 10 had high IPSS-WM. R/R patients had a median of 1 (1–4) prior lines of therapy. Other than progressive disease after chemoimmunotherapy, the most common considerations for choosing ZAN were patients’ age and/or comorbidities (n = 5), as well as ibrutinib toxicity. The initial ZAN dose was reduced in 4 patients. The median time on ZAN was 19.5 months (2.9–29.5). Of 12 evaluable patients, the ORR was 83% with 3 minor responses, 6 PRs, and 1 VGPR. With a median follow-up of 19.6 months, 7 patients were still on ZAN, 5 progressed, 4 while on ZAN, and 1 after ZAN was stopped due to AE. Eighteen-month PFS and OS were 60.5% and 77%, respectively. Eight (61%) patients had AEs of any grade, and 3 (23%) of grade 3–4; 2 stopped ZAN due to congestive heart failure and extreme fatigue.

Conclusion

The results of this real-world high-risk population are consistent with prospective studies highlighting the efficacy and safety of ZAN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaPiperidinesPyrazolesPyrimidinesProtein Kinase InhibitorsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overTreatment OutcomeIsrael

Stichwörter der Autor:innen

Real worldWaldenström macroglobulinemiaZanubrutinib

Substanzen

zanubrutinibPiperidinesPyrazolesPyrimidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hematology, Meir Medical Center, Kfar-Saba, Israel.
  • School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Hematology, Sheba Medical Center, Ramat-Gan, Israel.
  • Hematology, Ichilov Medical Center, Tel-Aviv, Israel.
  • Hematology, Barzilai Medical Center, Ashkelon, Israel.
  • Hematology, Poriya Medical Center, Tiberias, Israel.

Zitieren

APA

Itchaki, G., Benjamini, O., Levi, M., Nemets, A., Ygna, S., Assaly, M., Gourevitch, A., Gatt, M., Saban, R., Raanani, P., & Vaxman, I. (2024). “Real-Life” Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study. Acta Haematologica. https://doi.org/10.1159/000542936

Vancouver

Itchaki G, Benjamini O, Levi M, Nemets A, Ygna S, Assaly M, et al. “Real-Life” Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study. Acta Haematologica. 2024. doi:10.1159/000542936

BibTeX
@article{Itchaki2024,
  author = {Itchaki, Gilad and Benjamini, Ohad and Levi, Mor and Nemets, Anatoly and Ygna, Shai and Assaly, Mahdi and Gourevitch, Anna and Gatt, Moshe and Saban, Revital and Raanani, Pia and Vaxman, Iuliana},
  title = {“Real-Life” Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000542936}
}
Kostenlos starten →